SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla reports Profit after tax of Rs 10296.90 Mln, in the September 2023 quarter

27 Oct 2023 Evaluate
The revenue for the September 2023 quarter is pegged at Rs. 46647.20 millions, about 12.37% up against Rs. 41512.70 millions recorded during the year-ago period.A comparatively good net profit growth of 46.02% to Rs. 10296.90 millions was reported for the quarter ended September 2023 compared to Rs. 7051.90 millions of previous same quarter.Operating profit surged to 15842.10 millions from the corresponding previous quarter of 11533.30 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 46647.20 41512.70 12.37 89829.10 79974.10 12.32 157906.00 153808.20 2.66
Other Income 2050.90 922.80 122.25 3630.70 2099.60 72.92 4567.90 6667.00 -31.48
PBIDT 15842.10 11533.30 37.36 29468.80 22646.50 30.13 42493.70 43779.30 -2.94
Interest 78.00 75.00 4.00 81.10 97.10 -16.48 270.20 269.30 0.33
PBDT 15764.10 11458.30 37.58 29387.70 22549.40 30.33 40364.50 43510.00 -7.23
Depreciation 1798.10 1760.10 2.16 3157.60 3043.70 3.74 5959.10 5466.20 9.02
PBT 13966.00 9698.20 44.01 26230.10 19505.70 34.47 34405.40 38043.80 -9.56
TAX 3669.10 2646.30 38.65 6983.00 5150.50 35.58 9710.10 9218.00 5.34
Deferred Tax -13.00 -6.00 116.67 -102.50 -95.30 7.56 -400.90 -276.90 44.78
PAT 10296.90 7051.90 46.02 19247.10 14355.20 34.08 24695.30 28825.80 -14.33
Equity 1614.70 1614.00 0.04 1614.70 1614.00 0.04 1614.30 1613.60 0.04
PBIDTM(%) 33.96 27.78 22.24 32.81 28.32 15.85 26.91 28.46 -5.46

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×